CLINICAL_TRIALS
trial_result
· 2019-03-27
Clinical Trial Update: Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH [Phase 2]
Summary
Phase 2 trial of simtuzumab for liver fibrosis due to nonalcoholic steatohepatitis (NASH) was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gilead Sciences | Conditions: Liver Fibrosis Due to NASH | Phase 2 | Status: TERMINATED | Results posted: 2019-03-27